StockTipsArenaBeta

SELL Onesource Specialty Pharma Limited — Sahi Research

SELLOnesource Specialty Pharma Limited
Onesource Specialty Pharma share price target & all analyst calls

bySahi ResearchHorizon: NA (inferred Intraday)2 Sept 2026, 11:53 am ISTvia Sahi Research Telegram

Entry₹1,518.5Stated
Target₹1,490
Total upside +1.88% (call closed)
Stop loss₹1,542-1.55% risk
Exit₹1,5422 Sept 2026, 1:31 pm
Stop-loss hit-1.55%
Follow Sahi Research for new calls(7% target hit, 27 closed calls)Get alertsWatch ONESOURCE for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.

As of 3 Sept, 2:15 am IST
0 supporting4 neutral4 opposing
Supports the SELL call (0)

Nothing found in this tip’s window yet.

Neutral / worth noting (4)

OneSource Specialty Pharma releases Business Responsibility & Sustainability Report for FY26

NewsGoogle News·31 Aug · 2d ago

(opens in new tab)

OneSource Specialty Pharma files FY26 BRSR report with zero liquid discharge

NewsGoogle News·31 Aug · 2d ago

(opens in new tab)

OneSource Specialty Pharma hosts group investor meet on Sep 3

NewsGoogle News·31 Aug · 2d ago

(opens in new tab)

OneSource Specialty Pharma Sets Date for 19th AGM and Releases FY 2025-26 Annual Report

NewsGoogle News·31 Aug · 2d ago

(opens in new tab)
Weighs against the SELL call (4)

OneSource Specialty Pharma: FY26 में मामूली सुस्ती के बाद भी कंपनी का बड़ा दावा, FY28 के टारगेट पर कायम

NewsGoogle News·31 Aug · 2d ago

(opens in new tab)

OneSource Specialty Pharma Receives Karnataka Government's In-Principle Approval for Unit II Expansion Under KIP 2025-30

NewsGoogle News·31 Aug · 3d ago

(opens in new tab)

OneSource Specialty Pharma Renews EU-GMP Certification for Unit II Facility

NewsGoogle News·30 Aug · 3d ago

(opens in new tab)

OneSource Specialty Pharma Secures Saudi Approval for Generic Ozempic with Hikma Partnership

NewsGoogle News·30 Aug · 3d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Onesource Specialty Pharma

All analyst calls on Onesource Specialty Pharma

More from Sahi Research

Every call and its outcome